Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.

Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, Mangelsdorf DJ.

Mol Endocrinol. 2012 Aug;26(8):1443-54. doi: 10.1210/me.2011-1382. Epub 2012 Jun 14.

2.

Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.

Jeong Y, Xie Y, Xiao G, Behrens C, Girard L, Wistuba II, Minna JD, Mangelsdorf DJ.

PLoS Med. 2010 Dec 14;7(12):e1000378. doi: 10.1371/journal.pmed.1000378.

3.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

4.

The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.

DeCicco KL, Tanaka T, Andreola F, De Luca LM.

Carcinogenesis. 2004 Oct;25(10):1805-12. Epub 2004 Jun 17.

5.

Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.

Lohmann S, Herold A, Bergauer T, Belousov A, Betzl G, Demario M, Dietrich M, Luistro L, Poignée-Heger M, Schostack K, Simcox M, Walch H, Yin X, Zhong H, Weisser M.

Methods. 2013 Jan;59(1):10-9. doi: 10.1016/j.ymeth.2012.07.003. Epub 2012 Jul 14.

6.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

7.

Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.

Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, Keshamouni VG.

Neoplasia. 2008 Jun;10(6):597-603.

8.

Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.

Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M.

Oncogene. 2002 Mar 28;21(14):2171-80. Erratum in: Oncogene 2002 Nov 21;21(53):8220. Yamada, Masanabu [corrected to Yamada, Masanobu]; Mori, Matsumoto [corrected to Mori, Masatomo].

9.

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.

Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quaglino E.

BMC Genomics. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.

10.

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

Merk J, Rolff J, Dorn C, Leschber G, Fichtner I.

Eur J Cardiothorac Surg. 2011 Jul;40(1):e29-33. doi: 10.1016/j.ejcts.2011.02.010. Epub 2011 Mar 21.

PMID:
21420313
11.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.

13.

CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.

Cui F, Wang J, Chen D, Chen YJ.

Oncol Rep. 2011 Mar;25(3):701-8. doi: 10.3892/or.2010.1115. Epub 2010 Dec 20.

PMID:
21174061
14.

PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.

Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J.

Br J Cancer. 2012 Apr 24;106(9):1486-94. doi: 10.1038/bjc.2012.130.

15.

Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.

Muscat GE, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, Davis MJ, Clyne C, Funder JW, Simpson ER, Ragan MA, Kuczek E, Fuller PJ, Tilley WD, Leedman PJ, Clarke CL.

Mol Endocrinol. 2013 Feb;27(2):350-65. doi: 10.1210/me.2012-1265. Epub 2013 Jan 4.

PMID:
23292282
16.

Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, Li N, Qiu B, Gao Y, Li B, Tan X, Zhou F, Wang Z, Ding D, Wang J, Sun J, Hang J, Shi S, Feng X, He F, He J.

Mol Cell Proteomics. 2012 Feb;11(2):M111.008821. doi: 10.1074/mcp.M111.008821. Epub 2011 Nov 7.

17.
18.

DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.

Ansems M, Hontelez S, Looman MW, Karthaus N, Bult P, Bonenkamp JJ, Jansen JH, Sweep FC, Span PN, Adema GJ.

J Natl Cancer Inst. 2010 Jan 6;102(1):54-68. doi: 10.1093/jnci/djp441. Epub 2009 Dec 14.

19.

Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.

Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H.

J Exp Clin Cancer Res. 2010 Jul 1;29:87. doi: 10.1186/1756-9966-29-87.

20.

15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.

Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M.

Anticancer Drugs. 2007 Jan;18(1):65-78.

PMID:
17159504
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk